Target intelligence / Profile preview

Intestinal epithelial cell mucins and glycolipids

Molecular classification
Other, Glycoprotein, Glycolipid, Mucin
01

Overview

Intestinal epithelial cell mucins and glycolipids constitute the primary biochemical and physical barrier of the gastrointestinal tract. Mucins are large, heavily glycosylated proteins; MUC2 is the primary secreted mucin forming the protective mucus gel, while membrane-bound mucins like MUC1 and MUC13 contribute to the glycocalyx (Johansson et al., 2011, Nature Reviews Gastroenterology & Hepatology). Glycolipids, including glycosphingolipids and gangliosides, are integral components of the apical membrane that facilitate cell signaling and serve as attachment sites for both commensal bacteria and pathogens (Varki et al., 2015, Essentials of Glycobiology). These molecules are critical in preventing the translocation of gut microbes and protecting the underlying epithelium from mechanical stress and enzymatic digestion. In pathological states such as ulcerative colitis or Crohn's disease, the composition and thickness of the mucin layer are often significantly altered, leading to increased intestinal permeability and inflammation (Boltin et al., 2013, Journal of Clinical Gastroenterology). Therapeutic interventions often target these components to restore barrier integrity or to block the adhesion of toxins and pathogens, such as the binding of Cholera toxin to GM1 gangliosides.

Other names
Intestinal glycoconjugatesGastrointestinal mucus barrier componentsIntestinal mucosal glycansEnterocyte surface glycolipids and glycoproteins
02

Mechanism of action

Enhancement of mucus secretion, competitive inhibition of pathogen attachment (anti-adhesion), and formation of a protective physical complex over the epithelial surface.

03

Biological functions

Barrier functionImmune responseCell adhesionLubricationPathogen sequestrationSignal transduction
04

Disease associations

InfectionInflammationInflammatory bowel diseaseColorectal cancerCystic fibrosis
05

Safety considerations

Alteration of commensal microbiotaPotential for mucoadhesive drugs to interfere with nutrient absorptionRisk of masking underlying mucosal damageSystemic toxicity of certain mucolytic agents
06

Interacting drugs

Rebamipide

4 more in the full profile.

07

Biomarkers

MUC2 expression levelsFecal mucin contentO-glycan profileGalectin-3 levels

Beyond the preview

Go deeper on Intestinal epithelial cell mucins and glycolipids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal epithelial cell mucins and glycolipids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call